Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1 22Phase 1/2 11Phase 3 5Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Plasmacytoma 1POEMS Syndrome 1

Interventions

Cyclophosphamide 10fludarabine 8Dexamethasone 8Lenalidomide 6Bortezomib 5Granulocyte Colony-Stimulating Factor 468Ga-pentixafor 4Melphalan 3Filgrastim 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Blood Specimen Collection 2tocilizumab 1selinexor 1ruxolitinib 1pomalidomide 1pembrolizumab 1methyl prednisolonate 1ixazomib 1ioversol 1inebilizumab 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × auricularum × Plasma cell × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡